Stockscreener 앱 받기
14.51
1.33%
0.19
시간 외 거래:
14.81
0.30
+2.07%
전일 마감가:
$14.32
열려 있는:
$14.62
하루 거래량:
1.87M
Relative Volume:
0.67
시가총액:
$2.18B
수익:
-
순이익/손실:
$-647.68M
주가수익비율:
-2.5591
EPS:
-5.67
순현금흐름:
$-594.49M
1주 성능:
-2.36%
1개월 성능:
-8.34%
6개월 성능:
+14.52%
1년 성능:
+7.48%
1일 변동 폭
$14.25
$14.89
1주일 범위
$13.88
$15.57
52주 변동 폭
$7.48
$18.57
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
14.51 | 2.16B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Canaccord Genuity | Buy |
| 2026-02-06 | 개시 | Goldman | Buy |
| 2026-01-21 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-11-06 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 개시 | Citigroup | Buy |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
Federal jury awards Yale University, Biohaven $4M in trade secret suit - Westfair Communications
Yale, Biohaven Win $4M In Biotech Trade Secret Trial - Law360
Yale, Biohaven Win $4 Million Verdict Over Drug-Development Tech - Bloomberg Law News
Federal jury awards Yale, Biohaven $4M in lawsuit over trade secrets - Hartford Business Journal
Biohaven and Yale win $4M verdict in trade secret case - Investing.com Canada
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million - PR Newswire
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biohaven Ltd (BHVN) Institutional Confidence - TradingKey
Biohaven Ltd (BHVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biohaven Ltd (BHVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BHVN|Biohaven Ltd|Price:14.320|Chg%:-0.320 - TradingKey
BHVN|Biohaven Ltd|Price:14.563|Chg%:+0.243 - TradingKey
Biohaven Ltd (BHVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biohaven Ltd. Revenue Breakdown – NYSE:BHVN - TradingView
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 53% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Biohaven Pharmaceutical Holding Company Ltd (BHVN) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload - Finansavisen
How Biohaven’s (BHVN) R&D Leadership Shuffle Will Impact Investors - simplywall.st
Biohaven Ltd. (NYSE: BHVN) legal chief discloses holdings - Stock Titan
Lobbying Update: $120,000 of BIOHAVEN LTD. lobbying was just disclosed - Quiver Quantitative
Biohaven files Form 3 for Chief Legal Officer Warren Karl Volles - Bitget
Price to book forward of Biohaven Ltd. – NYSE:BHVN - TradingView
Discipline and Rules-Based Execution in BHVN Response - Stock Traders Daily
Biohaven (BHVN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Price to earnings forward of Biohaven Ltd. – BOATS:BHVN - TradingView
Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs - TradingView
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk (NYSE:BHVN) - Seeking Alpha
Enterprise value to EBIT forward of Biohaven Ltd. – BOATS:BHVN - TradingView
Price to sales forward of Biohaven Ltd. – NYSE:BHVN - TradingView
Price to sales forward of Biohaven Ltd. – BOATS:BHVN - TradingView
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Co - GuruFocus
Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey - Sahm
Enterprise value to revenue forward of Biohaven Ltd. – NYSE:BHVN - TradingView
BHVN News | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven announces leadership changes - Hartford Business Journal
Biohaven Announces Scientific Leadership Changes - Contract Pharma
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership - Yahoo Finance
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy? - Yahoo Finance
Biohaven Announces Scientific Leadership Transitions - GuruFocus
Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer - Moomoo
Biohaven: Bruce Car, Transitioning From Chief Scientific Officer to Chief Innovation Officer Focusing on External Collaborations >BHVN - Moomoo
Biohaven Announces Leadership Changes to Accelerate CNS Drug Discovery and Innovation Through Bexorg Collaboration – Minichart - Minichart
Biohaven announces leadership changes in discovery unit By Investing.com - Investing.com India
Biohaven announces leadership changes in discovery unit - Investing.com
Biohaven (NYSE: BHVN) shifts CSO to innovation role, promotes discovery head - Stock Titan
Biohaven (BHVN) Completes Enrollment in RISE3 Trial - Yahoo Finance
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Yahoo Finance
Janus Henderson holds 8.58M Biohaven shares (BHVN) — 5.7% stake - Stock Titan
Biohaven (BHVN) Is Up 5.6% After Advancing Two Late-Stage Trials in Epilepsy and Graves’ Disease - simplywall.st
10 Best Performing American Stocks in June 2026 - Insider Monkey
Why Wall Street Is Growing More Cautious on Biohaven (BHVN) - Insider Monkey
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):